MA50233A - Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité - Google Patents
Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésitéInfo
- Publication number
- MA50233A MA50233A MA050233A MA50233A MA50233A MA 50233 A MA50233 A MA 50233A MA 050233 A MA050233 A MA 050233A MA 50233 A MA50233 A MA 50233A MA 50233 A MA50233 A MA 50233A
- Authority
- MA
- Morocco
- Prior art keywords
- glp
- mic
- obesity
- treatment
- Prior art date
Links
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title 1
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17190270 | 2017-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50233A true MA50233A (fr) | 2020-07-22 |
Family
ID=59901361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050233A MA50233A (fr) | 2017-09-10 | 2018-09-10 | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11260108B2 (OSRAM) |
| EP (1) | EP3681529A1 (OSRAM) |
| JP (1) | JP2020533302A (OSRAM) |
| CN (1) | CN111163795A (OSRAM) |
| MA (1) | MA50233A (OSRAM) |
| WO (1) | WO2019048660A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3934679A1 (en) * | 2019-03-08 | 2022-01-12 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
| EP4071166A4 (en) * | 2019-12-11 | 2023-07-26 | Lg Chem, Ltd. | Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation |
| WO2021136223A1 (en) * | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| CN111234015B (zh) * | 2020-02-12 | 2021-04-06 | 康维众和(中山)生物药业有限公司 | 用于延长药物半衰期的抗体、其融合蛋白和应用 |
| EP4237438A4 (en) * | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| JP2024519950A (ja) * | 2021-05-21 | 2024-05-21 | ユハン コーポレーション | Ｇｄｆ１５変異体及びｇｌｐ－１受容体作動薬を含む併用投与用組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１誘導体 |
| US8192735B2 (en) | 2004-04-13 | 2012-06-05 | St Vincent's Hospital Sydney Limited | Method for modulating appetite |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
| WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| WO2014120619A2 (en) | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| WO2015017710A1 (en) | 2013-07-31 | 2015-02-05 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
| WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
| EP3160496B1 (en) | 2014-06-24 | 2021-03-03 | Novo Nordisk As | Mic-1 fusion proteins and uses thereof |
| ES2883158T3 (es) | 2014-07-30 | 2021-12-07 | Ngm Biopharmaceuticals Inc | Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos |
| AP2017009828A0 (en) | 2014-10-31 | 2017-03-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| US11105818B2 (en) | 2016-01-15 | 2021-08-31 | Novo Nordisk A/S | MIC-1 receptor and uses thereof |
-
2018
- 2018-09-10 CN CN201880058528.0A patent/CN111163795A/zh not_active Withdrawn
- 2018-09-10 MA MA050233A patent/MA50233A/fr unknown
- 2018-09-10 EP EP18769323.9A patent/EP3681529A1/en not_active Withdrawn
- 2018-09-10 JP JP2020513684A patent/JP2020533302A/ja not_active Withdrawn
- 2018-09-10 WO PCT/EP2018/074263 patent/WO2019048660A1/en not_active Ceased
- 2018-09-10 US US16/645,828 patent/US11260108B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200197491A1 (en) | 2020-06-25 |
| CN111163795A (zh) | 2020-05-15 |
| EP3681529A1 (en) | 2020-07-22 |
| US11260108B2 (en) | 2022-03-01 |
| WO2019048660A1 (en) | 2019-03-14 |
| JP2020533302A (ja) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| FR24C1010I2 (fr) | Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux | |
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| MA45073A (fr) | Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers | |
| EP3471780A4 (en) | TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT | |
| MA49458A (fr) | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques | |
| EP3393475C0 (en) | CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN THE TREATMENT OF CANCER | |
| MA44119A (fr) | Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale | |
| EP3572050A4 (en) | EXCREMENTAL TREATMENT FOR USE IN COLOSTOMIES | |
| MA55821A (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| EP3512517A4 (en) | USE OF PRIDOPIDIN FOR THE TREATMENT OF ANXIETY AND DEPRESSION | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| EP3645120A4 (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION | |
| MA49794A (fr) | Composition utilisée dans le traitement prophylactique et thérapeutique de troubles de l'appareil cardiovasculaire | |
| EP3654961A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN WITH CAPSAICIN | |
| MA43861A (fr) | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie | |
| EP3848022C0 (en) | THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION | |
| EP4069700A4 (en) | MACROCYCLES FOR USE IN TREATMENT OF DISEASES | |
| EP3442538A4 (en) | TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE | |
| MA52691A (fr) | Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies | |
| EP3840729A4 (en) | TREATMENT OF SPINAL CORD INJURY (SCI) AND BRAIN INJURY USING GSX1 | |
| EP3373922A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA | |
| EP3337475A4 (en) | NITROXIDE WITH AMYLOID BINDING AGENT FOR IMAGING AND THERAPEUTIC USES | |
| EP3294313A4 (en) | METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE |